

**DCF Psychotropic Medication Advisory Committee
Monthly Meeting Notes**

May 2, 2008, 1:00PM

Riverview Hospital for Children and Youth
Middletown, CT.

PRESENT: Janet Williams M.D., DCF Medical Director; David S. Aresco, Pharmacist Consultant; Blyse Soby RN DCF CO; Irv Jennings M.D., Family & Childrens; Carlos A. Gonzalez M.D. IPP; Jacqueline Harris MD, DCF Western Regional Medical Director; Joan Narad M.D. DCF CO; Naida Arcenas APRN, DDS; Aurele Kamm APRN, DCF CO; Lesly Siegel M.D., DCF Regional Medical Director; Dr. Mark Schaefer DSS (Guest); John Swanson CTBHP (Guest); Laurie VanDerHeide CTBHP (Guest); Brian Keyes MD; Miland Kale M.D. CTJS; Chris Malinowski APRN, Village; Marian Cancelliere, DCF Waterbury; Robert Zavoski, DSS (Guest); Naveen Hassam APRN DCF Waterbury; Curtis Harmon APRN, DCF CO

1. Call to order: Janet Williams MD called the meeting to order at 1:08 pm.
2. Set date/time of next meeting: The next meeting is scheduled for June 6, 2008 from 1-3PM; RHCY AB Conference Room. **Next meeting changed to Friday June 13, 2008 at 1PM**
3. Announcements:
 - DDNA and AADND combined conference for MD's and RN's will take place at Foxwoods on June 8th-10th. Cost is about \$400.00 for the 3 days. Naida has printed information for those who are interested.
 - Psychopharmacology Conference Work Group Report: The group met and have several recommendations:
 - The target audience should be primary care providers.
 - The conference should take place in early fall this year.
 - Recommended location is CVH auditorium.
 - Subject matter should include – evaluation/referrals, ADHD, anxiety, depression and possibly psychosis (although PCP's may not have a keen interest in this area).
 - Should be a ½ day conference.
 - Should provide CME.
 - Possibly have another state organization co-sponsor.
 - The committee will continue to meet to further develop plans.
4. Minutes: The minutes of the April 4, 2008 PMAC were reviewed and approved.
5. Discussion with Dr. Mark Schaefer and Dr. Robert Zavoski (DDS) about the CT BHP role in reviewing Medicaid Pharmacy Utilization Data for psychotropic medications.
 - Dr. Williams presented a review of this subject matter and the proposed role of PMAC.
 - Part of the contracted agreement is that an annual “data-dump” would be analyzed. A group (such as PMAC) is needed to do the actual analysis.
 - Laurie VandenHeide of CTBHP presented information regarding the available data.
 - Access to all fields in the DSS file.
 - Data dictionary (recommend this be reviewed by a pharmacist).

- Noted that diagnosis data is not in the pharmaceutical data-base but may be available via other data-bases.
 - The package of pre-built reports was reviewed.
 - A review of these reports by the PMAC was deferred.
 - A discussion ensued regarding:
 - If PMAC is the right group to do this work and what influence PMAC would have regarding recommendations etc.
 - How doing this work would be advantageous to PMAC (and DCF) considering the subsets of populations that PMAC is responsible for (children/adolescents in care or custody of DCF). This possibility of extracting data that is specific to DCF children was discussed.
 - There was discussion regarding how best to operationalize this project.
 - A work group (subcommittee) was formed that will report to PMAC.
 - The work group will meet (usually via teleconference) and develop recommendations for the PMAC on how to move forward with this project.
 - PMAC members were asked for any final thoughts or comments. It was noted and confirmed that any identified issues would result in QI/educational initiatives vs instituting practice standards.
 - **PMAC voted and approved moving forward with this project.**
6. Review of Medication Guidelines/Protocols:
- Atypical maximum dosing guideline – Reviewed and approved.
 - Stimulant review – need of an EKG was discussed in detail. Guidelines accepted as presented. We will not require an EKG prior to routine Stimulant dosing despite new contrary recommendations from the American Heart Association.
 - Stimulant dosing guidelines – approved.
 - Research will be conducted to determine if the recommended maximum dosing is based on a lack of efficacy at higher doses or an increase in the incidence of ADR's. This information will be presented at the June 13th meeting and the dosing guidelines modified if needed.
 - Vivance was approved to be added to the approved drug list.
 - The next category for review will be Lithium/anticonvulsants.
7. Update: CMCU and the need to re-contact community provider network.
- Reinforcement and/or education is needed for several issues (any suggestions should be forwarded to Dr. Williams).
 - Suggest more be made available on the DCF Web site regarding PMAC information for providers.
 - By the end of summer there should be a major mailing to providers.
8. Other: Chinese Medicine: A presentation by Dr David London_ Suggest putting this on the July agenda.
9. Adjournment: 2:50pm

Respectfully Submitted:

David S. Aresco